Magnetar Financial LLC trimmed its position in shares of Organon & Co. (NYSE:OGN – Free Report) by 66.9% during the second quarter, Holdings Channel.com reports. The fund owned 902,825 shares of the company’s stock after selling 1,825,758 shares during the quarter. Magnetar Financial LLC’s holdings in Organon & Co. were worth $18,688,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. LSV Asset Management increased its stake in Organon & Co. by 47.3% in the 2nd quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock valued at $136,843,000 after buying an additional 2,121,940 shares during the last quarter. Norges Bank purchased a new stake in shares of Organon & Co. during the fourth quarter valued at approximately $26,321,000. Wedge Capital Management L L P NC bought a new stake in Organon & Co. during the second quarter worth $33,573,000. Allianz Asset Management GmbH lifted its holdings in Organon & Co. by 156.5% during the fourth quarter. Allianz Asset Management GmbH now owns 1,900,554 shares of the company’s stock worth $27,406,000 after acquiring an additional 1,159,519 shares during the period. Finally, Kahn Brothers Group Inc. boosted its position in Organon & Co. by 3,242.4% in the first quarter. Kahn Brothers Group Inc. now owns 1,180,204 shares of the company’s stock worth $22,188,000 after purchasing an additional 1,144,894 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.
Organon & Co. Trading Down 3.4 %
Shares of OGN stock opened at $19.49 on Monday. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05. The firm has a market cap of $5.01 billion, a P/E ratio of 4.77, a PEG ratio of 0.89 and a beta of 0.85. The company has a 50 day moving average of $21.00 and a 200-day moving average of $20.12. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10.
Organon & Co. Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Investors of record on Friday, August 16th were paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 5.75%. The ex-dividend date was Friday, August 16th. Organon & Co.’s dividend payout ratio is currently 27.38%.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and raised their target price for the company from $18.00 to $20.00 in a research report on Friday, September 6th.
View Our Latest Analysis on OGN
Organon & Co. Profile
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
See Also
- Five stocks we like better than Organon & Co.
- Best Stocks Under $10.00
- See Why Oracle’s Cloud Infrastructure Growth Demands Attention
- Retail Stocks Investing, Explained
- Darden Restaurants Is on the Verge of a Significant Breakout
- How to Plot Fibonacci Price Inflection Levels
- Onsemi Could Be Set Up For a Solid Rebound: Here’s Why
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Free Report).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.